The significance and therapeutic potential of PD-1 and its ligands in ovarian cancer: A systematic review

Gynecologic Oncology

Volumn 142, Issue 1, 2016, Pages 184-189

  Zhu, Xinxin ^a   Lang, Jinghe ^a  

^a PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

Author keywords

Biomarker; Immunotherapy; Ovarian cancer; PD 1; PD L1; Toxicity

Indexed keywords

BMS 936559; CD134 ANTIGEN; CISPLATIN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GLUCOCORTICOID INDUCED TUMOR NECROSIS FACTOR RECEPTOR; IPILIMUMAB; NIVOLUMAB; PACLITAXEL; PEMBROLIZUMAB; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 LIGAND 2; PROGRAMMED DEATH 1 RECEPTOR; TRABECTEDIN; PDCD1 PROTEIN, HUMAN;

CANCER IMMUNOTHERAPY; DRUG EFFICACY; HUMAN; META ANALYSIS (TOPIC); MULTICENTER STUDY (TOPIC); NONHUMAN; OVARY CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TREATMENT RESPONSE; ANIMAL; FEMALE; IMMUNOLOGY; OVARIAN NEOPLASMS;

ANIMALS; FEMALE; HUMANS; OVARIAN NEOPLASMS; PROGRAMMED CELL DEATH 1 RECEPTOR;

EID: 84963705103     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2016.04.002     Document Type: Review

References (61)

1. L.A. Torre, F. Bray, R.L. Siegel, J. Ferlay, J. Lortet-Tieulent, and A. Jemal Global cancer statistics, 2012 CA Cancer J. Clin. 65 2 2015 87 108
2. R. Siegel, D. Naishadham, and A. Jemal Cancer statistics, 2012 CA Cancer J. Clin. 62 1 2012 10 29
3. H. Wei, L. Zhao, I. Hellstrom, K.E. Hellstrom, and Y. Guo Dual targeting of CD137 co-stimulatory and PD-1 co-inhibitory molecules for ovarian cancer immunotherapy OncoImmunology 3 2014 e28248
4. V. Lavoue, A. Thedrez, J. Leveque, F. Foucher, S. Henno, V. Jauffret, and et al. Immunity of human epithelial ovarian carcinoma: the paradigm of immune suppression in cancer J. Transl. Med. 11 2013 147
5. P.A. Ascierto, R. Addeo, G. Carteni, B. Daniele, M. De Laurentis, G.P. Ianniello, and et al. The role of immunotherapy in solid tumors: report from the Campania Society of Oncology Immunotherapy (SCITO) meeting, Naples 2014 J. Transl. Med. 12 2014 291
6. F. De Felice, C. Marchetti, I. Palaia, D. Musio, L. Muzii, V. Tombolini, and et al. Immunotherapy of ovarian cancer: the role of checkpoint inhibitors Int. J. Immunol. Res. 2015 2015 191832
7. J.R. Brahmer, S.S. Tykodi, L.Q. Chow, W.J. Hwu, S.L. Topalian, P. Hwu, and et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer N. Engl. J. Med. 366 26 2012 2455 2465
8. Y. Ishida, Y. Agata, K. Shibahara, and T. Honjo Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death EMBO J. 11 11 1992 3887 3895
9. M.E. Keir, M.J. Butte, G.J. Freeman, and A.H. Sharpe PD-1 and its ligands in tolerance and immunity Annu. Rev. Immunol. 26 2008 677 704
10. W. Zou, and L. Chen Inhibitory B7-family molecules in the tumour microenvironment Nat. Rev. Immunol. 8 6 2008 467 477
11. S. Ceeraz, E.C. Nowak, and R.J. Noelle B7 family checkpoint regulators in immune regulation and disease Trends Immunol. 34 11 2013 556 563
12. H. Dong, S.E. Strome, D.R. Salomao, H. Tamura, F. Hirano, D.B. Flies, and et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion Nat. Med. 8 8 2002 793 800
13. R.S. Freedman, A.P. Kudelka, J.J. Kavanagh, C. Verschraegen, C.L. Edwards, M. Nash, and et al. Clinical and biological effects of intraperitoneal injections of recombinant interferon-gamma and recombinant interleukin 2 with or without tumor-infiltrating lymphocytes in patients with ovarian or peritoneal carcinoma Clin. Cancer Res. 6 6 2000 2268 2278
14. K. Abiko, N. Matsumura, J. Hamanishi, N. Horikawa, R. Murakami, K. Yamaguchi, and et al. IFN-gamma from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer Br. J. Cancer 112 9 2015 1501 1509
15. P. Youngnak, Y. Kozono, H. Kozono, H. Iwai, N. Otsuki, H. Jin, and et al. Differential binding properties of B7-H1 and B7-DC to programmed death-1 Biochem. Biophys. Res. Commun. 307 3 2003 672 677
16. L. Zhang, J.R. Conejo-Garcia, D. Katsaros, P.A. Gimotty, M. Massobrio, G. Regnani, and et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer N. Engl. J. Med. 348 3 2003 203 213
17. W.T. Hwang, S.F. Adams, E. Tahirovic, I.S. Hagemann, and G. Coukos Prognostic significance of tumor-infiltrating T cells in ovarian cancer: a meta-analysis Gynecol. Oncol. 124 2 2012 192 198
18. D.S. Chen, and I. Mellman Oncology meets immunology: the cancer-immunity cycle Immunity 39 1 2013 1 10
19. G.T. Motz, and G. Coukos Deciphering and reversing tumor immune suppression Immunity 39 1 2013 61 73
20. C. Robert, A. Ribas, J.D. Wolchok, F.S. Hodi, O. Hamid, R. Kefford, and et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial Lancet 384 9948 2014 1109 1117
21. T.H. Borch, M. Donia, M.H. Andersen, and I.M. Svane Reorienting the immune system in the treatment of cancer by using anti-PD-1 and anti-PD-L1 antibodies Drug Discov. Today 20 9 2015 1127 1134
22. S.L. Topalian, F.S. Hodi, J.R. Brahmer, S.N. Gettinger, D.C. Smith, D.F. McDermott, and et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer N. Engl. J. Med. 366 26 2012 2443 2454
23. J. Hamanishi, M. Mandai, T. Ikeda, M. Minami, A. Kawaguchi, T. Murayama, and et al. Safety and antitumor activity of anti-PD-1 antibody, nivolumab, in patients with platinum-resistant ovarian cancer J. Clin. Oncol. 33 34 2015 4015 4022
24. Merck Serono Day - the Merck Group, http://www.merckgroup.com/en/investors/merck -serono-day.html.
25. B.W. Tse, A. Collins, M.K. Oehler, A. Zippelius, and V.A. Heinzelmann-Schwarz Antibody-based immunotherapy for ovarian cancer: where are we at? Ann. Oncol. 25 2 2014 322 331
26. M. Dai, H. Wei, Y.Y. Yip, Q. Feng, K. He, V. Popov, and et al. Long-lasting complete regression of established mouse tumors by counteracting Th2 inflammation J. Immunother. 36 4 2013 248 257
27. T.L. Walunas, D.J. Lenschow, C.Y. Bakker, P.S. Linsley, G.J. Freeman, J.M. Green, and et al. CTLA-4 can function as a negative regulator of T cell activation Immunity 1 5 1994 405 413
28. A.K. Salama, and F.S. Hodi Cytotoxic T-lymphocyte-associated antigen-4 Clin. Cancer Res. 17 14 2011 4622 4628
29. P. Waterhouse, J.M. Penninger, E. Timms, A. Wakeham, A. Shahinian, K.P. Lee, and et al. Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4 Science 270 5238 1995 985 988
30. A. Ito, S. Kondo, K. Tada, and S. Kitano Clinical development of immune checkpoint inhibitors BioMed Res. Int. 2015 2015 605478
31. M.K. Callahan, M.A. Postow, and J.D. Wolchok CTLA-4 and PD-1 pathway blockade: combinations in the clinic Front. Oncol. 4 2014 385
32. A. Korman, B. Chen, C. Wang, L. Wu, P. Cardarelli, and M. Selby Activity of anti-PD-1 in murine tumor models: role of "host" PD-L1 and synergistic effect of anti-PD-1 and anti-CTLA-4 J. Immunol. 178 2007 S82
33. M.A. Curran, W. Montalvo, H. Yagita, and J.P. Allison PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors Proc. Natl. Acad. Sci. U. S. A. 107 9 2010 4275 4280
34. J.D. Wolchok, H. Kluger, M.K. Callahan, M.A. Postow, N.A. Rizvi, A.M. Lesokhin, and et al. Nivolumab plus ipilimumab in advanced melanoma N. Engl. J. Med. 369 2 2013 122 133
35. M.A. Postow, J. Chesney, A.C. Pavlick, C. Robert, K. Grossmann, D. McDermott, and et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma N. Engl. J. Med. 372 21 2015 2006 2017
36. J. Larkin, V. Chiarion-Sileni, R. Gonzalez, J.J. Grob, C.L. Cowey, C.D. Lao, and et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma N. Engl. J. Med. 373 1 2015 23 34
37. http://www.accessdata.fda.gov/drugsatfda-docs/label/2015/125554s002lbl.pdf
38. P. Zhang, D.M. Su, M. Liang, and J. Fu Chemopreventive agents induce programmed death-1-ligand 1 (PD-L1) surface expression in breast cancer cells and promote PD-L1-mediated T cell apoptosis Mol. Immunol. 45 5 2008 1470 1476
39. X. Qin, C. Liu, Y. Zhou, and G. Wang Cisplatin induces programmed death-1-ligand 1(PD-L1) over-expression in hepatoma H22 cells via Erk /MAPK signaling pathway Cell. Mol. Biol. (Noisy-le-Grand) 56 2010 Ol1366 Ol1372 (Suppl)
40. D.S. Shin, and A. Ribas The evolution of checkpoint blockade as a cancer therapy: what's here, what's next? Curr. Opin. Immunol. 33 2015 23 35
41. X. Zhang, B. Xu, C. Sun, L. Wang, and X. Miao Knockdown of CIP2A sensitizes ovarian cancer cells to cisplatin: an in vitro study Int. J. Clin. Exp. Med. 8 9 2015 16941 16947
42. National Institutes of Health Clinicaltrials.gov. NCI clinical trial number: NCT02477826 [cited 2015 Sep 15]. Available from: https://www.clinicaltrials.gov/ ct2/show/NCT02477826? term=nivolumab+and+lung&rank=4
43. C. Ferlini, G. Raspaglio, S. Mozzetti, M. Distefano, F. Filippetti, E. Martinelli, and et al. Bcl-2 down-regulation is a novel mechanism of paclitaxel resistance Mol. Pharmacol. 64 1 2003 51 58
44. J. Peng, J. Hamanishi, N. Matsumura, K. Abiko, K. Murat, T. Baba, and et al. Chemotherapy induces programmed cell death-ligand 1 overexpression via the nuclear factor-kappaB to foster an immunosuppressive tumor microenvironment in ovarian cancer Cancer Res. 75 23 2015 5034 5045
45. M. D'Incalci, and C.M. Galmarini A review of trabectedin (ET-743): a unique mechanism of action Mol. Cancer Ther. 9 8 2010 2157 2163
46. B.J. Monk, T.J. Herzog, S.B. Kaye, C.N. Krasner, J.B. Vermorken, F.M. Muggia, and et al. Trabectedin plus pegylated liposomal doxorubicin in recurrent ovarian cancer J. Clin. Oncol. 28 19 2010 3107 3114
47. B.J. Monk, T.J. Herzog, S.B. Kaye, C.N. Krasner, J.B. Vermorken, F.M. Muggia, and et al. Trabectedin plus pegylated liposomal doxorubicin (PLD) versus PLD in recurrent ovarian cancer: overall survival analysis Eur. J. Cancer 48 15 2012 2361 2368
48. G. Germano, R. Frapolli, C. Belgiovine, A. Anselmo, S. Pesce, M. Liguori, and et al. Role of macrophage targeting in the antitumor activity of trabectedin Cancer Cell 23 2 2013 249 262
49. Z. Guo, H. Wang, F. Meng, J. Li, and S. Zhang Combined trabectedin and anti-PD1 antibody produces a synergistic antitumor effect in a murine model of ovarian cancer J. Transl. Med. 13 2015 247
50. L. Zitvogel, L. Apetoh, F. Ghiringhelli, and G. Kroemer Immunological aspects of cancer chemotherapy Nat. Rev. Immunol. 8 1 2008 59 73
51. M. Croft Control of immunity by the TNFR-related molecule OX40 (CD134) Annu. Rev. Immunol. 28 2010 57 78
52. I. Gramaglia, A. Jember, S.D. Pippig, A.D. Weinberg, N. Killeen, and M. Croft The OX40 costimulatory receptor determines the development of CD4 memory by regulating primary clonal expansion J. Immunol. 165 6 2000 3043 3050
53. Z. Guo, X. Wang, D. Cheng, Z. Xia, M. Luan, and S. Zhang PD-1 blockade and OX40 triggering synergistically protects against tumor growth in a murine model of ovarian cancer PLoS One 9 2 2014 e89350
54. T.H. Watts TNF/TNFR family members in costimulation of T cell responses Annu. Rev. Immunol. 23 2005 23 68
55. P. Zhou, L. L'Italien, D. Hodges, and X.M. Schebye Pivotal roles of CD4 + effector T cells in mediating agonistic anti-GITR mAb-induced-immune activation and tumor immunity in CT26 tumors J. Immunol. 179 11 2007 7365 7375
56. T. Ramirez-Montagut, A. Chow, D. Hirschhorn-Cymerman, T.H. Terwey, A.A. Kochman, S. Lu, and et al. Glucocorticoid-induced TNF receptor family related gene activation overcomes tolerance/ignorance to melanoma differentiation antigens and enhances antitumor immunity J. Immunol. 176 11 2006 6434 6442
57. L. Lu, X. Xu, B. Zhang, R. Zhang, H. Ji, and X. Wang Combined PD-1 blockade and GITR triggering induce a potent antitumor immunity in murine cancer models and synergizes with chemotherapeutic drugs J. Transl. Med. 12 2014 36
58. C.J. Maine, N.H. Aziz, J. Chatterjee, C. Hayford, N. Brewig, L. Whilding, and et al. Programmed death ligand-1 over-expression correlates with malignancy and contributes to immune regulation in ovarian cancer Cancer Immunol. Immunother. 63 3 2014 215 224
59. J. Hamanishi, M. Mandai, M. Iwasaki, T. Okazaki, Y. Tanaka, K. Yamaguchi, and et al. Programmed cell death 1 ligand 1 and tumor-infiltrating CD8 + T lymphocytes are prognostic factors of human ovarian cancer Proc. Natl. Acad. Sci. U. S. A. 104 9 2007 3360 3365
60. K. Abiko, M. Mandai, J. Hamanishi, Y. Yoshioka, N. Matsumura, T. Baba, and et al. PD-L1 on tumor cells is induced in ascites and promotes peritoneal dissemination of ovarian cancer through CTL dysfunction Clin. Cancer Res. 19 6 2013 1363 1374
61. J.R. Brahmer, C.G. Drake, I. Wollner, J.D. Powderly, J. Picus, W.H. Sharfman, and et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates J. Clin. Oncol. 28 19 2010 3167 3175